Skip to main content

Research Repository

Advanced Search

Inclusion in the World Health Organization Model List of Essential Medicines of non-vitamin K anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality

Zaidel, Ezequiel J.; Leng, Xinyi; Moshood Adeoye, Abiodun; Hakim, Ferdous; Karmacharya, Biraj; Katbeh, Asim; Neubeck, Lis; Partridge, Stephanie; Perel, Pablo; Huffman, Mark D.; Di Cesare, Mariachiara

Authors

Ezequiel J. Zaidel

Xinyi Leng

Abiodun Moshood Adeoye

Ferdous Hakim

Biraj Karmacharya

Asim Katbeh

Stephanie Partridge

Pablo Perel

Mark D. Huffman

Mariachiara Di Cesare



Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for initial treatment of AF for stroke prevention. Here we describe the evidence collated and the process followed for the successful inclusion of NOACs into the 21st WHO Model List of Essential Medicines (EML).
Individual NOACs have been reported to be non-inferior or superior to warfarin in preventing stroke and systemic embolism in eligible AF patients with a reduction in the risk of stroke and systemic embolism and a lower risk of major bleeding in patients with non-valvular AF compared with warfarin in both RCTs and real-world data.
The successful inclusion of NOACs in the WHO EML is an important step forward in the global fight against cardiovascular morbidity and mortality, especially in low- and middle-income countries, where the burden of disease is high and limited access to diagnosis and treatment translates into a higher burden of morbidity, mortality, and economic costs.

Citation

Zaidel, E. J., Leng, X., Moshood Adeoye, A., Hakim, F., Karmacharya, B., Katbeh, A., …Di Cesare, M. (2020). Inclusion in the World Health Organization Model List of Essential Medicines of non-vitamin K anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality. Global Heart, 15(1), https://doi.org/10.5334/gh.608

Journal Article Type Article
Acceptance Date Jun 26, 2020
Online Publication Date Aug 6, 2020
Publication Date Aug 6, 2020
Deposit Date Jun 26, 2020
Publicly Available Date Jun 26, 2020
Print ISSN 2211-8160
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 15
Issue 1
DOI https://doi.org/10.5334/gh.608
Keywords non-valvular atrial fibrillation, non-vitamin K antagonist oral anticoagulants (NOACs), Essential Medicine List, stroke, prevention
Public URL http://researchrepository.napier.ac.uk/Output/2672345

Files

Inclusion In The World Health Organization Model List Of Essential Medicines Of Non-vitamin K Anticoagulants For Treatment Of Non-valvular Atrial Fibrillation: A Step Towards Reducing The Burden Of Cardiovascular Morbidity And Mortality (accepted version) (213 Kb)
PDF

Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/

Copyright Statement
Published under a Creative Commons Attribution 4.0 International (CC BY 4.0) license.



Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality (published version (1.2 Mb)
PDF

Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/

Copyright Statement
Published under a Creative Commons Attribution 4.0 International (CC BY 4.0) license.






You might also like



Downloadable Citations